Sym 013Alternative Names: Sym013
Latest Information Update: 19 Nov 2016
At a glance
- Originator Symphogen
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cancer
Most Recent Events
- 01 Oct 2016 Phase-I/II clinical trials in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02906670)